As of 2025-05-14, the EV/EBITDA ratio of Urogen Pharma Ltd (URGN) is -3.49. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. URGN's latest enterprise value is 419.44 mil USD. URGN's TTM EBITDA according to its financial statements is -120.28 mil USD. Dividing these 2 quantities gives us the above URGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.8x - 12.2x | 11.5x |
| Forward P/E multiples | 11.6x - 12.9x | 12.2x |
| Fair Price | (29.13) - (30.69) | (29.95) |
| Upside | -387.3% - -402.7% | -395.4% |
| Date | EV/EBITDA |
| 2025-05-13 | -3.58 |
| 2025-05-12 | -3.87 |
| 2025-05-09 | -3.58 |
| 2025-05-08 | -3.69 |
| 2025-05-07 | -3.48 |
| 2025-05-06 | -3.31 |
| 2025-05-05 | -3.80 |
| 2025-05-02 | -4.01 |
| 2025-05-01 | -3.97 |
| 2025-04-30 | -4.06 |
| 2025-04-29 | -3.72 |
| 2025-04-28 | -3.92 |
| 2025-04-25 | -3.38 |
| 2025-04-24 | -3.48 |
| 2025-04-23 | -3.51 |
| 2025-04-22 | -3.45 |
| 2025-04-21 | -3.30 |
| 2025-04-17 | -3.31 |
| 2025-04-16 | -3.58 |
| 2025-04-15 | -3.72 |
| 2025-04-14 | -3.66 |
| 2025-04-11 | -3.48 |
| 2025-04-10 | -3.20 |
| 2025-04-09 | -3.47 |
| 2025-04-08 | -3.30 |
| 2025-04-07 | -3.42 |
| 2025-04-04 | -3.53 |
| 2025-04-03 | -3.64 |
| 2025-04-02 | -3.89 |
| 2025-04-01 | -3.67 |
| 2025-03-31 | -3.84 |
| 2025-03-28 | -3.89 |
| 2025-03-27 | -3.99 |
| 2025-03-26 | -4.02 |
| 2025-03-25 | -3.97 |
| 2025-03-24 | -4.16 |
| 2025-03-21 | -4.25 |
| 2025-03-20 | -4.21 |
| 2025-03-19 | -4.07 |
| 2025-03-18 | -4.02 |
| 2025-03-17 | -3.99 |
| 2025-03-14 | -3.84 |
| 2025-03-13 | -3.78 |
| 2025-03-12 | -3.75 |
| 2025-03-11 | -3.75 |
| 2025-03-10 | -3.40 |
| 2025-03-07 | -3.36 |
| 2025-03-06 | -3.51 |
| 2025-03-05 | -3.50 |
| 2025-03-04 | -3.28 |